Emcure

Ref: EPL/CS/SE/0058/2026 **Date:** July 13, 2026

To,

National Stock Exchange of India Limited **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex, Bandra (East),** **Mumbai – 400 051** **Script Symbol: EMCURE**	**BSE Limited** **P J Towers,** **Dalal Street,** **Mumbai- 400 001** **Scrip Code/Symbol: 544210/ EMCURE**

Dear Sir/Madam,

Subject: Press Release

Please find enclosed herewith a Press Release titled "Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics; Samit Mehta Leads the Next Phase of Growth", which shall be released after this intimation.

You are requested to take the same on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

AMRUTA AMIT YANGALWAR

Digitally signed by AMRUTA AMIT YANGALWAR
Date: 2026.07.13 16:37:37 +05'30'

Amruta Yangalwar
Company Secretary & Compliance Officer
Membership Number: A25687

Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics; Samit Mehta Leads the Next Phase of Growth

Pune, July 13, 2026: Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) today announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited ("Gennova"), alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company.

Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr. Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary.

Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms.

Commenting on the announcement, **Mr. Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals Limited**, said: *"We thank Dr. Sanjay Singh for his nearly two decades of exceptional scientific leadership at Gennova. His stewardship has built platforms, products, and a culture that will continue to fulfil Gennova's mission of transforming healthcare. With this stake acquisition, we simplify Gennova's ownership, sharpen its strategic focus, and position it under Mr. Samit Mehta's leadership for its next phase of growth in biologics and biosimilars."*

Mr. Samit Mehta, Whole Time Director &CEO, Gennova Biopharmaceuticals Limited, said: *"As part of the One Emcure framework, Gennova will continue to anchor the Group's biologics and biosimilars capabilities. Our work will complement Emcure's broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas."*

The transaction is not expected to have a material impact on Emcure's consolidated financials or its capital allocation framework. The Company's deleveraging trajectory, capex plans and R&D investment plans remain unchanged.

Please refer to the Company's disclosure on BSE / NSE for further details.

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT March 2026. Emcure is present in 70+ countries globally, including Europe and Canada.

FOR MORE INFORMATION	
Media Naveen Soni corpcomm@emcure.com	***Investors*** Saurabh Paliwal investor.relations@emcure.com